{"id":"W2406500056","doi":"10.1158/1538-7445.sabcs15-pd5-04","title":"Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Neratinib; Trastuzumab; Medicine; Pertuzumab; Internal medicine; Breast cancer; Regimen; Docetaxel; Oncology; Neoadjuvant therapy; Lapatinib; Metastatic breast cancer; Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001634089,0.001283766,0.001448013,0.000321085,0.0003284969,0.001001523,0.0008850313,0.001112611,0.007778327],"category_scores_gemma":[0.0009424198,0.0004391117,0.001192387,0.0002809587,0.001045429,0.0007776049,0.0003266988,0.003553829,0.001040554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001085746,"about_ca_system_score_gemma":0.00146384,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001339872,"about_ca_topic_score_gemma":0.00333933,"domain_scores_codex":[0.99954,0.0002715062,0.00002419537,0.00006659393,0.00004131044,0.00005638112],"domain_scores_gemma":[0.9994496,0.0001077337,0.00008107933,0.00002696397,0.00004021327,0.0002943047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9621599,0.008747699,0.0009838834,0.0004535808,0.0009469496,0.00003884315,0.00003853933,0.0006235345,0.004508337,0.0001749315,0.002105039,0.01921877],"study_design_scores_gemma":[0.9171866,0.07792758,0.00159007,0.00002957614,0.0004447571,0.00004059427,0.00002096758,0.0007450272,0.0008162618,0.0001359742,0.001049525,0.00001295472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849294,0.003085795,0.0005911035,0.001165183,0.0004384986,0.003750908,0.002236163,0.0001338024,0.003669166],"genre_scores_gemma":[0.9836927,0.001730861,0.001728793,0.001431045,0.0002224689,0.003260196,0.002940929,0.00002063576,0.004972275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007778327,"threshold_uncertainty_score":0.02602106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05068744065344186,"score_gpt":0.424429407720223,"score_spread":0.3737419670667811,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}